TwinBeech Capital’s Corcept Therapeutics CORT Stock Holding History

TwinBeech Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-31,392	Closed	-$698K	–	674
2023 Q2	$698K	Buy	+31,392	New	+$723K	0.01%	482
2023 Q1	–	Sell	-20,277	Closed	-$412K	–	660
2022 Q4	$412K	Buy	+20,277	New	+$508K	0.01%	610
2021 Q2	–	Sell	-12,250	Closed	-$291K	–	467
2021 Q1	$291K	Sell	12,250 -11,839	-49%	-$316K	0.04%	382
2020 Q4	$630K	Buy	+24,089	New	+$508K	0.1%	249

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

TwinBeech Capital's CORT Position: Q3 2023 in Review

TwinBeech Capital sold out of Corcept Therapeutics (CORT) in Q3 2023, closing a stake of 31,392 shares — an estimated $698K sold.

TwinBeech Capital first reported a position in CORT in Q4 2020 and held it in 4 quarters. The position peaked at $698K in Q2 2023. 246 funds tracked by Wall St. Rank hold CORT as of Q3 2023.

TwinBeech Capital reported no remaining Corcept Therapeutics position as of Q3 2023 after selling out during the quarter.
TwinBeech Capital sold 31,392 Corcept Therapeutics shares in Q3 2023, an estimated $698K.
TwinBeech Capital first reported a position in Corcept Therapeutics in Q4 2020 and held it in 4 quarters.
TwinBeech Capital's Corcept Therapeutics position peaked at $698K in Q2 2023.
246 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2023.

Based on TwinBeech Capital's 13F filing for Q3 2023, filed 14 Nov 2023.